Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Alessa Therapeutics Inc.
Study ID
NCT06257693
Phase
PHASE1
Status
Recruiting

Conditions

  • Prostate Adenocarcinoma

Eligibility Criteria

Sex
MALE
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • enzalutamide — DRUG
    Localized single delivery of the Enolen implant (polymer + enzalutamide) with planned radical prostatectomy

Study Details

The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.

Key Dates

Start date
Jun 21, 2024
Status verified
Feb 2026
Primary completion
Jun 30, 2028
Completion
Aug 30, 2028

Study Design

Enrollment
56 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Enolen (tm)
    Enolen (tm) implants containing enzalutamide

Primary Outcome Measure

To assess the adverse events associated with the Enolen implant [ Time Frame: up to 12 months ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Northwestern UniversityChicagoIllinois60611
Sophia Kallas
312-694-0633
Ashley Ross, MD
Mary Bird Cancer CenterMetairieLouisiana70002
Scott Delacroix, MD (PRINCIPAL_INVESTIGATOR)
National Institutes of Health Clinical CenterBethesdaMaryland20892
Katie Evans, RN
240-401-2157
Peter Pinto, MD (PRINCIPAL_INVESTIGATOR)
VA Portland Health Care SystemPortlandOregon97239
Laura Onstad
503-721-1060
Ryan Kopp, MD (PRINCIPAL_INVESTIGATOR)
Atlantic Urology SpecialistsMyrtle BeachSouth Carolina29572
Taylor Stephenson
843-449-1010
Abhishek Srivastava, MD (PRINCIPAL_INVESTIGATOR)
Virginia Commonwealth UniversityRichmondVirginia23298
Genelle Gaudinez
804-628-6430
Alexander Kenigsberg, MD (PRINCIPAL_INVESTIGATOR)
Aurora UrologyMilwaukeeWisconsin53215
Greg Anderson
262-442-9368
Zachary Kozel, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chicago, IL

Related Studies